eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

EDUCATIONAL RESOURCES FOR NVAF

The below videos feature Dr. Gary Benson, a Haematologist at the Belfast Trust, and Dr. Martin O’Kane, a GPwSI in Atrial Fibrillation in Ballycastle County Antrim. The videos reflect the expert opinion of Gary Benson in response to frequently asked questions on the management of NVAF.

Dr. O’Kane opens each video with a question which Dr. Benson answers.

Can you explain to us the reason why NOACs are unsuitable for patients with
valvular AF?

reasons why noacs are unsuitable for patients with valvular af

Is it appropriate for GPs to anticoagulate patients with NVAF while waiting for their outpatient echo?

is it appropriate for gps to anticoagulate nvaf patients which waiting for their outpatient echo

What would your guidance be on the appropriate management of patients on warfarin with unstable INRs?

guidance on the appropriate management of patients on warfarin with unstable inrs

Can you explain the difference between an unstable INR and the time in therapeutic range?

the difference between an unstable inr and the time in therapeutic range

What would you, as a haematologist, like to see in the GP review of a patient with NVAF on a NOAC?

what would a haemotologist like to see in the gp review of a non-valvular af patient on a noac
Diagnosemethoden

ELIQUIS is available for your patients with NVAF1

ELIQUIS is available for your patients with DVT / PE1


Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily   
DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
SmPC = Summary of Product Characteristics

* ELIQUIS® (apixaban): an oral, direct factor Xa inhibitor indicated for:

- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (New York Heart Association Class ≥II)1
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
- Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery1

Not all patients who start on ELIQUIS for acute DVT / PE will stay on ELIQUIS; some acute DVT / PE patients who receive treatment do not require treatment for the prevention of recurrent DVT / PE. Other patients may be prescribed ELIQUIS for the prevention of recurrent VTE after initial treatment for acute DVT / PE with another anticoagulant.1 This is a decision for the prescribing clinician together with patient involvement in the decision-making.

Reference

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.